Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: Data from a randomized trial of patients with bacteremia and endocarditis

Clinical Infectious Diseases

Volumn 50, Issue 12, 2010, Pages 1568-1574

  Bhavnani, Sujata M ^a   Rubino, Christopher M ^a   Ambrose, Paul G ^a   Drusano, George L ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; DAPTOMYCIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACTERIAL ENDOCARDITIS; BAYES THEOREM; BAYESIAN LEARNING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EXPOSURE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PLASMA CONCENTRATION-TIME CURVE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; UNIVARIATE ANALYSIS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; CREATINE KINASE; DAPTOMYCIN; ENDOCARDITIS, BACTERIAL; HUMANS; MIDDLE AGED; PROBABILITY; STAPHYLOCOCCAL INFECTIONS;

EID: 77952983904     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/652767     Document Type: Article

References (20)

1. Woodworth JR, Nyhart EH Jr., Brier GL, Wolny JD, Black HR. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 1992; 36:318-325
2. Tally FP, Zeckel M, Wasilewski MM, et al. Daptomycin: a novel agent for Gram-positive infections. Expert Opin Investig Drugs 1999; 8:1223-1238 (Pubitemid 29410579)
3. Tally FP, DeBruin MF. Development of daptomycin for Gram-positive infections. J Antimicrob Chemother 2000; 46:523-526
4. Oleson FB Jr., Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000; 44:2948-2953
5. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-665
6. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI, the Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673-1681.
7. Leary R, Jelliffe R, Schumitzky A, Van Guilder M. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) models. In: Proceedings of the 14th IEEE Symposium on ComputerBased Medical Systems. Bethesda, MD: IEEE Computer Society, 2001: 389-394
8. SYSTAT Software Inc. SYSTAT 11, Statistics II. Richmond, CA: SYSTAT Software, 2004.
9. D'Argenio DZ, Schumitzky A. ADAPT II: a program package for simulation, identification and optimal experimental design: user's manual. Los Angeles: Biomedical Simulations Resource, University of Southern California, 1997.
10. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47:1318-1323 (Pubitemid 36368592)
11. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006; 50:3245-3249 (Pubitemid 44527494)
12. Katz DE, Lindfield KC, Steenbergen JN, et al. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract 2008; 62:1455-1464
13. Pai MP, Norenberg JP, Anderson T, et al. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2007; 51:2741-2747 (Pubitemid 47206208)
14. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean body weight. Clin Pharmacokinet 2005; 44:1051-1065
15. Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL. Pharmacodynamics of daptomycin in a murine-thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2001; 45:845-851.
16. Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004; 48:63-68.
17. Cubicin (daptomycin for injection) [full prescribing information]. Lexington, MA: Cubist Pharmaceuticals, 2008.
18. Newham DJ, Jones DA, Edwards RH. Large delayed plasma creatine kinase changes after stepping exercise. Muscle Nerve 1983; 6:380-385 (Pubitemid 13026992)
19. Noakes TD, Kotzenberg G, McArthur PS, Dykman J. Elevated serum creatine kinase MB and creatine kinase BB-isoenzyme fractions after ultra-marathon running. Eur J Appl Physiol Occup Physiol 1983; 52: 75-79 (Pubitemid 14245203)
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.